Conference Schedule

Day1: July 23, 2018

Keynote Forum

Biography

Kenji Ohe has completed his PhD at Kyushu University, Japan, and started working as a Postdoctoral fellow at Paolo Sassone Corsi’s lab when it was at IGBMC, France, and Akila Mayeda’s lab when it was at Miami, Florida, USA. He is now working on therapeutical tactics on manipulating alternative splicing as an Associate Professor at Faculty of Pharmaceutical Sciences, Fukuoka University, Japan.

Abstract

HMGA1a (formerly termed HMGI) is known as a DNA-binding transcription factor with oncogenic properties. We have reported that it also binds to RNA in a sequence-specific manner. HMGA1a anchors U1 snRNP to the 5’ splice site of presenilin-2 exon 5 to induce its aberrant exon skipping only when the HMGA1a RNA-binding site is adjacent to the 5’ splice site in sporadic Alzheimer’s disease. In order to seek for other target genes of HMGA1a, we were prompted to search for HMGA1a RNA-binding sites in the estrogen receptor alpha (ERα) gene where both have been extensively studied in breast cancer. We performed a sequence homology search for the presenilin-2 (PS2) HMGA1a RNA-binding site and found a specific sequence 33-nt upstream of the 5’ splice site of ERα exon 1. Therefore, we examined; (i) HMGA1abinding to the RNA sequence by RNA-EMSA, (ii) splicing activity in cultured MCF-7 cells that were transfected with HMGA1a-expression and its RNA decoy expression plasmids, (iii) splicing activity in vitro. We found it switched two alternatively spliced isoforms, ERα66 and ERα46. HMGA1a-mediated U1 snRNP anchoring to the adjacent pseudo-5’ splice site was checked by psoralen-mediated UV crosslinking combined with RNA-EMSA. The effect of the decoy oligonucleotides containing the PS2 HMGA1a RNA-binding site in MCF-7 cells was further checked by transplanting its stable transfectant in nude mice showing increased estrogen-dependent growth. However, in tamoxifen-resistant MCF-7 TAMR1 cells, the HMGA1a RNA-binding decoy oligonucleotides improved tamoxifen-responsiveness by inhibiting estrogendependent cell proliferation. We conclude that this HMGA1a RNA-binding decoy oligonucleotides would be implicated in novel therapeutic application to improve tamoxifen effectiveness in breast cancer where tamoxifen lack effect.

Biography

Donglu Shi is currently the Chair of the Materials Science and Engineering Program at the University of Cincinnati. He received his PhD in Engineering from the University of Massachusetts, Amherst. He was the Staff Scientist in the Materials Science Division of Argonne National Laboratory between 1988 and 1995. He has so far published 270 refereed SCI journal publications including Physical Review Letters, Nature, ACS Nano, and Advanced Materials. His main interests include Nanostructure Design, Nano Biomedicine, Nanophotonics, and Magnetism. The most recent works pioneer several novel approaches in developing multifunctional nano carrier systems for early cancer diagnosis and therapy.

Abstract

Precision medicine has gained wide attention in various disciplines such as oncology. Selection of drugs and patients is imperative to cope with increasing complexity and costs of new systemic treatments. Almost all these advances are based on molecular biology of the target lesion. High quality tissues meaning enough, pure and fresh are prerequisite for these expensive and complex medical innovations. Often, the biopsy step is the bottleneck because of concerns for patient discomfort, morbidity/mortality, and poor tissue quality. While surgery is expensive and cumbersome, tru-cut technologies are inappropriate also because of the relatively small size and the heterogeneity of samples. New macrobiopsy technology can provide samples with sufficient quality in a comfortable out-patient setting. Recently, new progress has been made for biopsy in the most delicate areas of the human body. This study collected cases of patients that were seen in six clinical departments on admission for lesions that were inaccessible for other percutaneous tissue acquisition methods in areas such as head and neck, thorax, liver, intra-abdominal, retroperitoneal, and intrapelvic sites. The biopsy was taken by Spirotome of sizes between 14 and 8 G. The procedure was considered successful if the patient had no side effects and the size of the sample was sufficient for all prospected histological and biomolecular tests. The end-point of this non-randomized study was to detect locations where a macrobiopsy could not be taken. For all areas, considered to be delicate for tissue acquisition, at least one successful procedure was possible. In almost all cases, the procedure could be considered successful. Tips and tricks will be presented. With the appropriate tools for imaging and biopsy, high quality tissue samples can be obtained from all body parts, even the most delicate, providing access to precision medicine for every patient.pturing and sensitive detection in clinical settings.

Biography

Precision medicine has gained wide attention in various disciplines such as oncology. Selection of drugs and patients is imperative to cope with increasing complexity and costs of new systemic treatments. Almost all these advances are based on molecular biology of the target lesion. High quality tissues meaning enough, pure and fresh are prerequisite for these expensive and complex medical innovations. Often, the biopsy step is the bottleneck because of concerns for patient discomfort, morbidity/mortality, and poor tissue quality. While surgery is expensive and cumbersome, tru-cut technologies are inappropriate also because of the relatively small size and the heterogeneity of samples. New macrobiopsy technology can provide samples with sufficient quality in a comfortable out-patient setting. Recently, new progress has been made for biopsy in the most delicate areas of the human body. This study collected cases of patients that were seen in six clinical departments on admission for lesions that were inaccessible for other percutaneous tissue acquisition methods in areas such as head and neck, thorax, liver, intra-abdominal, retroperitoneal, and intrapelvic sites. The biopsy was taken by Spirotome of sizes between 14 and 8 G. The procedure was considered successful if the patient had no side effects and the size of the sample was sufficient for all prospected histological and biomolecular tests. The end-point of this non-randomized study was to detect locations where a macrobiopsy could not be taken. For all areas, considered to be delicate for tissue acquisition, at least one successful procedure was possible. In almost all cases, the procedure could be considered successful. Tips and tricks will be presented. With the appropriate tools for imaging and biopsy, high quality tissue samples can be obtained from all body parts, even the most delicate, providing access to precision medicine for every patient.

Abstract

Precision medicine has gained wide attention in various disciplines such as oncology. Selection of drugs and patients is imperative to cope with increasing complexity and costs of new systemic treatments. Almost all these advances are based on molecular biology of the target lesion. High quality tissues meaning enough, pure and fresh are prerequisite for these expensive and complex medical innovations. Often, the biopsy step is the bottleneck because of concerns for patient discomfort, morbidity/mortality, and poor tissue quality. While surgery is expensive and cumbersome, tru-cut technologies are inappropriate also because of the relatively small size and the heterogeneity of samples. New macrobiopsy technology can provide samples with sufficient quality in a comfortable out-patient setting. Recently, new progress has been made for biopsy in the most delicate areas of the human body. This study collected cases of patients that were seen in six clinical departments on admission for lesions that were inaccessible for other percutaneous tissue acquisition methods in areas such as head and neck, thorax, liver, intra-abdominal, retroperitoneal, and intrapelvic sites. The biopsy was taken by Spirotome of sizes between 14 and 8 G. The procedure was considered successful if the patient had no side effects and the size of the sample was sufficient for all prospected histological and biomolecular tests. The end-point of this non-randomized study was to detect locations where a macrobiopsy could not be taken. For all areas, considered to be delicate for tissue acquisition, at least one successful procedure was possible. In almost all cases, the procedure could be considered successful. Tips and tricks will be presented. With the appropriate tools for imaging and biopsy, high quality tissue samples can be obtained from all body parts, even the most delicate, providing access to precision medicine for every patient.

Biography

Donglu Shi is currently the Chair of the Materials Science and Engineering Program at the University of Cincinnati. He received his PhD in Engineering from the University of Massachusetts, Amherst. He was the Staff Scientist in the Materials Science Division of Argonne National Laboratory between 1988 and 1995. He has so far published 270 refereed SCI journal publications including Physical Review Letters, Nature, ACS Nano, and Advanced Materials. His main interests include Nanostructure Design, Nano Biomedicine, Nanophotonics, and Magnetism. The most recent works pioneer several novel approaches in developing multifunctional nano carrier systems for early cancer diagnosis and therapy.

Abstract

Precision medicine has gained wide attention in various disciplines such as oncology. Selection of drugs and patients is imperative to cope with increasing complexity and costs of new systemic treatments. Almost all these advances are based on molecular biology of the target lesion. High quality tissues meaning enough, pure and fresh are prerequisite for these expensive and complex medical innovations. Often, the biopsy step is the bottleneck because of concerns for patient discomfort, morbidity/mortality, and poor tissue quality. While surgery is expensive and cumbersome, tru-cut technologies are inappropriate also because of the relatively small size and the heterogeneity of samples. New macrobiopsy technology can provide samples with sufficient quality in a comfortable out-patient setting. Recently, new progress has been made for biopsy in the most delicate areas of the human body. This study collected cases of patients that were seen in six clinical departments on admission for lesions that were inaccessible for other percutaneous tissue acquisition methods in areas such as head and neck, thorax, liver, intra-abdominal, retroperitoneal, and intrapelvic sites. The biopsy was taken by Spirotome of sizes between 14 and 8 G. The procedure was considered successful if the patient had no side effects and the size of the sample was sufficient for all prospected histological and biomolecular tests. The end-point of this non-randomized study was to detect locations where a macrobiopsy could not be taken. For all areas, considered to be delicate for tissue acquisition, at least one successful procedure was possible. In almost all cases, the procedure could be considered successful. Tips and tricks will be presented. With the appropriate tools for imaging and biopsy, high quality tissue samples can be obtained from all body parts, even the most delicate, providing access to precision medicine for every patient.pturing and sensitive detection in clinical settings.

Tracks

  • Cancer Research & Cancer vaccines | Biomarker and drug targeting | Clinical Radiational Oncology | Cancer Biology | Immuno Oncology studies
Location: Amsterdam, Netherlands
Speaker

DONGLU SHI

University of Cincinnati, USA

Chair

Speaker

WEISI YAN

University of South Alabama, USA

Co Chair

Biography

Maria Del Rosario Dávalos Gamboa has completed her Pharmaceutical Biochemistry degree from the University Of San Simon Bolivia. She has obtained her PhD in the Pontifical University San Francisco Xavier of Chuquisaca.  She has more than 15 scientific articles published in prestigious Journals. She was the Director of the Research Institute of the Faculty of Dentistry UMSS, she won a competency exam at the Faculty of Dentistry UMSS in the Chair of Biochemistry and currently, she is Titular professor of Biochemistry in the same faculty.

Abstract

Objective: To determine the influence of the immune system, food and infectious diseases, for the development of cancer in a focal sample of children and adolescents who usually attend the Manuel Ascencio Villarroel Children's Hospital in the Cochabamba region (Bolivia).

Methods: Cross-sectional study conducted in January and February 2016 in children and adolescents who regularly attend the Manuel Ascencio Villarroel child's Hospital, between the ages of 2 months and 16 years (n = 45) of the Cochabamba region (Bolivia). The parents and / or guardians of the participants were surveyed for a descriptive analysis.

Results: They had two or more signs and symptoms (low immunity) by the weakened immune system 86.67%. They were usually affected by, virus and influenza 51.11%, with muscular pain and constant joints 44.44%, watery eyes and nose running in 35.55%, persistent headache in 40%, they got tired a lot and fatigued despite of rest 35.56%, 31.11% were regularly ill, had a delay in recovering from diseases 28.88%, exhibited a fixed pattern of disease 28.88%, fought endlessly with the disease 24.44%. In the type of food those who consumed natural products before their diagnosis of cancer, 41.66% the use of natural carbohydrates, 61.11% natural protein, 61.11% natural fats, 63.88% of natural fruits, 55 % natural fibers, 27.77% drank a lot of water. In the type of inadequate food that they consumed before their diagnosis of cancer, 33.33% cured meats, 75% soft drinks, 83.3% refined sugar, junk food and refined flour. No statistically significant differences were detected in the influence of infectious diseases.

Conclusions: In the study it was determined that for the development of cancer in children and adolescents of the focal sample, both their weakened immune system and their diet influenced them, although their diet was varied with natural products, usually they consumed sodas, refined sugar, white flour and junk food, foods that are related to the origin of cancer.

Biography

Dina Ron has completed her PhD from Ben-Gurion University and Postdoctoral studies from the National Cancer Institute, NIH, USA. She is a Lab Chief in the Biology Department, the Israel Institute of Technology. She has published more than 60 papers in Refereed professional journals and served as an Editorial Board Member of the Journal of Biological Chemistry. 

Abstract

Carcinomas account for over 80% of all human cancer types with no effective therapies. The tumor suppressor Sef [similar expression to fibroblast growth factors (FGF)] is expressed in all the human epithelial tissues and is down-regulated in all the carcinoma types that have been examined so far in a manner that correlates with tumor aggressiveness. We examined the therapeutic potential of restoring the expression of the hSef-b isoform in a prostate carcinoma model.  In our in vitro studies, hSef-b inhibited the proliferation of TRAMP C2 cells and attenuated the activation of ERK/MAPK as well as the master transcription factor NF-κB in response to FGF and IL-1/TNF, respectively. Both FGF and NF-κB are strongly implicated in prostate carcinoma progression. Next, the hSef-b, gene was delivered using therapeutic ultrasound (TUS) to pre-established prostate tumors in vivo. Tumors were injected with a bicistronic vector co-expressing hSef-b with eGFP to serve as a reporter for transfection rates, and treated with TUS. Transfection efficiency of plasmid co-expressing hSef-b/eGFP into TRAMP C2 tumors following a single TUS application was 14.7±2.5%. Repeated TUS treatments with hSef-b plasmid, significantly suppressed prostate tumor growth (60%) through inhibition of cell proliferation (60%), and also reduced blood vessel density (56%). In addition, the levels of the promitogenic and proangiogenic factor, FGF2, were significantly reduced following repeated TUS treatments with hSef-b plasmid. Collectively, our results strongly suggest that hSef-b acts in a cell autonomous as well as in a paracrine manner and further revealed the efficacy of non-viral, TUS-based hSef-b gene delivery approach for the treatment of prostate cancer tumors, and possibly other carcinomas where Sef is downregulated. Moreover, using this approach, we discovered that hSef-b is also furnished with the capacity to inhibit tumor angiogenesis.

Biography

Jana Slobodníková has completed Specialization of Radiology I and II from Charles University in Prague, Faculty of Medicine. She has completed Post-doctorate and CSc (PhD) at the Institute of Experimental Oncology, Slovak Academy of Sciences. She was an Assistant Professor at Tyrnaviensis  University, Hosting Professor at St. Elizabeth High School in Bratislava. She has been teaching at several universities in Prague, Trenčín, Trnava and Bratislava. She is Author of teaching text, university textbooks, and lead workshops. She organizes international congresses and workshops. She has published more than 90 scientific papers, from then 25 papers in renowned journals and has been active as Editorial Board Member of repute in 5 scientific periodicals. She has published 3 monographies, and has founded the Section of Breast Imaging in 1996. Since 1996, she is the President of the Section of Breast Imaging of Slovak radiologic Society and Vice President of the Slovak Society of Ultrasound in Medicine. She has Membership in organizations: ECR, EUSOBI, EFSUMB, SSUM (Slovak Society of Ultrasound in Medicine) and SRS (Slovak Radiology Society).

Abstract

Introduction: In the Slovak Republic, breast cancer is the most common type of oncological disease in women, the leading cause of cancer mortality in all women. In the past 10 years, breast cancer mortality has continued to slowly decrease; the breast cancer incidence in the past 20 years has continued to increase, likely due to program of preventive mammography         

The Aim:  The aim of this retrospective study was to asses the importance, the position of the interventional methods; core cut biopsy and fine needle aspiration biopsy under ultrasound control in the differential diagnostics of changes after surgical treatment for breast cancer

Patients & Methods: We evaluated examinations of 385 patients with newly diagnosed breast carcinoma after conservative surgical therapy in period between January 2005 and December 2016 from Clinic of Radiology in Trenčín. In all the cases, we performed ultrasound, mammography 2D and 3D examinations, ultrasound guided biopsy with free hand methods, needle 14, 16 and 20 G.

Results: The major findings as postoperative changes were seromas, haematomas, fat necrosis, skin thickening, inflammatory changes, granulomas, postoperative scars and local tumor recurrence.

Conclusion: The ultrasound guided interventional methods; fine needle aspiration cytology and core cut biopsy are reliable and perfect methods for the differential diagnosis of postoperative changes and the follow up of postoperative changes.

Biography

George Kunudji has attained his PhD from the University of Ghana, Legon and Postdoctoral studies from University of Ghana Medical School. He is the Director of Bikbok Herbal Centre, a reputable herbal organisation that is dispensing services across the country, Ghana and currently discovered herbal antidote to the treatment of cancer tumour. Moreover, he has been serving as the Chairman of the health advocacy group of Asuboa Traditional Council and Nifahene (Nifa chief) of Asuboa Traditional Area.

Abstract

Immune system can react to cancer cells in two ways, by reacting against tumor-specific antigens, molecules which are unique to cancer cells or against tumor-associated antigens; molecules are expressed differently by cancer cells and normal cells. Immunity to carcinogen-induced tumors in mice is directed against the products of unique mutations of normal cellular genes. These mutant proteins are tumor-specific antigens. Tumors caused by viruses display viral antigens that serve as tumor antigens. Examples are the products of the E6and E7 genes of the human papillomavirus, the causative agent of cervical carcinoma, and EBNA-1.  Most recently, we have developed evidence for a powerful immunodominance effect that occurs between different tumor antigens and have identified what appears to be a unique mechanism by which at least some forms of immunotherapy induce tumor specific destruction.  Tumors of unknown cause which account for most human tumors express antigens that the immune system can recognize remained in doubt until the development of methods for detecting and isolating them. The advent of hybridism technology led to the development of monoclonal antibodies from mice that were immunized with human tumors. Monoclonal antibodies that reacted specifically with tumor cells were then used to characterize putative human tumor antigens. However, there were doubts that the tumor-specific antigens that mouse monoclonal antibodies could detect would perceived by the human immune system. The evolution of methods to cultivate human T cells, and in particular tumor-specific T cells from patients with cancer, led to an important breakthrough, the identification of MAGE-1, a melanoma-specific antigen that stimulates human T cells in vitro. With antigen-specific T cells as a reagent, it was possible to clone the MAGE-1 gene. The MAGE-1studies showed that the human immune system can respond to tumor antigens, and the findings stimulated a productive effort to discover tumor antigens. The result is a long and still-growing list of antigens from a variety of tumors that could serve as targets for treatment. 

Day2: July 24, 2018

Keynote Forum

Biography

Dwayne N Jackson is an Associate Professor at Western University, Schulich School of Medicine and Dentistry. He completed his Doctoral and Postdoctoral training at Yale University School of Medicine (New Haven, CT, USA) and Western University (London, Ontario, Canada). He is a world recognized Physiologist, Intravital Microscopist, and Director of the A C Burton Laboratory for Vascular Research at Western University.

Abstract

Chronic stress is associated with elevated levels of sympathetic neurotransmitter release and immunosuppression. A growing body of evidence suggests that stress-related factors may contribute to the initiation, development and progression of breast cancer. We recently identified neuropeptide Y (NPY) as such a factor. Using the 4T1 murine breast cancer model, we characterized NPY receptor expression in cancer cells and tumors and observed positive NPY receptor (Y1R, Y2R and Y5R) expression. In vitro NPY treatment of 4T1 cells stimulated Y5R mediated increases in proliferation, whereas, NPY increased chemotaxis through Y2R and Y5R activation. We then tested whether NPY could function as an angiogenic factor by augmenting expression and secretion of the pro-angiogenic factor VEGF from breast cancer cells. We found that NPY functioned as a paracrine system with cancer cells to promote angiogenesis. Specifically, NPY Y5R activation of cancer cells (4T1 and MDA-MB-231) stimulated increased expression and release of VEGF. These novel findings served as motivation to develop an in vivo model in which the components of NPY system (i.e., nerves, ligands and receptors) could be functionally studied. We first demonstrated sympathetic neural innervation and NPY expression in 4T1 tumors. Secondly, when tumor sympathetic neural innervation was attenuated (via chemical sympathectomy), we observed a significant decrease in tumor growth and vascular development. Furthermore, we observed similar tumor growth-suppressing effects from oral Y5R antagonist treatment. Finally, we established a protocol for intravital microscopy imaging of tumors to investigate their neural innervation, cellular components, and microvasculature. Herein, we provide novel evidence that: 1) NPY elicits proliferative, migratory, and angiogenic effects on breast cancer cells (via Y5R); 2) describes an in vivo murine model for functional studies examining the role of sympathetic nerves, neurotransmitters, cancer associated cells, and blood vessels, and 3) highlights the Y5R as a potential therapeutic target against breast cancer progression and metastasis.

Biography

Mohamed Mostafa Rizk was the Director of the Alexandria University Hospital Labs, and Alexandria Medical Research Labs for 3 years. He was the Head of Department of  Clinical and Chemical Pathology since 2014 till 2017. He has published more than 35 publications  in reputed international  journals. He has been serving as an Asscessor of the projects introduced  to  Royan  6th  international research award. He is a Member of Board of  Directors of the  Egyptian Society of Laboratory Medicine. In 1993 he was honoured by Ministry of Scientific Research and got the prize from Egypt Country  for persons. In 2002, he got the 1st prize in accepted talks in the 18th International Congress of Clinical Chemistry and Laboratory Medicine IFCC , Kyoto , Japan. In 2009, he was selected as the Ideal Doctor  by the Syndicate of Doctors of Egypt . 

 

 

Abstract

Background: Ovarian cancer is the seventh most common cancer in females with the highest mortality rate of all gynecological cancers due to its late discovery and ambiguous symptoms. Thus, there is a need for new promising strategies to diagnose ovarian cancer.

Aim: We aimed at finding a characteristic plasma proteome pattern that could be used for the detection of epithelial ovarian cancer.

Methods: The combination of MagSi-proteomics C8 beads, Ultraflextreme MALDI-TOF and ClinProTools software was used to compare the plasma protein spectra from 50 patients with epithelial ovarian cancer, 20 patients with benign ovarian masses and 50 healthy females.

Results: Our study showed that a plasma profile of 21 differentiated peaks between patients with epithelial ovarian cancer and healthy controls with a sensitivity of 73 % and a specificity of 82.8% upon external validation, while a 5-peak differentiated profile of patients with epithelial ovarian cancer from patients with benign ovarian masses with a sensitivity of 81% and a specificity of 73.7%.

Conclusion: MALDI-TOF proteomic profiling represents a promising potential tool for diagnosing epithelial ovarian cancer.

Biography

Jiangwen Zhang has graduated from Johns Hopkins University with PhD. He has worked at Harvard University Genome Center as Senior System Biologist for years before joining University of Hong Kong in 2013. He has broad interest in Genetic and Epigenetic Regulation in Development and Diseases. Currently, his lab is focusing on epigenetic regulation of tumorigenesis. His lab employs high through-put Omics assays and large scale computation to dissect the gene regulatory network and signalling pathways involved in oncogenesis.

Abstract

Chromatin regulators (CRs) are frequently dysregulated to reprogram the epigenetic landscape of the cancer genome. However, the underpinnings of the dysregulation of CRs and their downstream effectors remain to be elucidated. Here, we designed an integrated framework based on multi-omics data to identify candidate master regulator CRs affected by genomic alterations across eight cancer types in The Cancer Genome Atlas. Most of them showed consistent activated or repressed (i.e., oncogenic or tumor-suppressive) roles in cancer initiation and progression. In order to further explore the insight mechanism of the dysregulated CRs, we also developed an R package ModReg based on differential connectivity to recognize CRs as modulators of the transcription factors (TFs) involved in tumorigenesis. Our analysis revealed that the connectivity between TFs and their target genes tended to be disrupted in the patients who had a high expression of oncogenic CRs or low expression of tumor-suppressive CRs. As a proof-of-principle study, 14 (82.4%) of the top ranked 17 driver CRs in liver cancer were validated by literature mining or experiments including shRNA knockdown and dCas9 epigenetic editing. Moreover, we confirmed that chromatin regulator SIRT7 physically interacted with transcription factor NFE2L2, and positively
modulated the transcriptional program of NFE2L2 by affecting ~64% of its targets. epigenetic landscape of the cancer genome. However, the underpinnings of the dysregulation of CRs and their downstream effectors remain to be elucidated. Here, we designed an integrated framework based on multi-omics data to identify candidate master regulator CRs affected by genomic alterations across eight cancer types in The Cancer Genome Atlas. Most of them showed consistent
activated or repressed (i.e., oncogenic or tumor-suppressive) roles in cancer initiation and progression. In order to further explore the insight mechanism of the dysregulated CRs, we also developed an R package ModReg based on differential connectivity to recognize CRs as modulators of the transcription factors (TFs) involved in tumorigenesis. Our analysis revealed that the connectivity between TFs and their target genes tended to be disrupted in the patients who had a high expression of oncogenic CRs or low expression of tumor-suppressive CRs. As a proof-of-principle study, 14 (82.4%) of the top ranked 17 driver CRs in liver cancer were validated by literature mining or experiments including shRNA knockdown and dCas9 epigenetic editing. Moreover, we confirmed that chromatin regulator SIRT7 physically interacted with transcription factor NFE2L2, and positively
modulated the transcriptional program of NFE2L2 by affecting ~64% of its targets

Biography

Mohammed Y Almaghrabi is a currently working as Radiation Oncologist at King Abdullah Medical City, Saudi Arabia. He is leading Stereotactic RadioSurgery/Stereotactic Body Radiation Therapy task groups at the same Hospital. He is a CNS tumour board Chairman. He was the Head of Radiation Oncology department at Prince Faisal Cancer Centre, Saudi Arabia. He holds his Research experience from University of Ottawa Canada and Nantes  University, France. He has been a recipient of many awards and grants. He was selected as a Sectional Editor (Radiation Oncology, Biomarkers) for Journal of Cancer Treatment and Diagnosis, Reviewer for British Journal of Radiology and CARO annual scientific meeting. His research experience includes various programs, contributions and participation in different countries for diverse fields of study.

Abstract

The most impressive clinical outcome was found when we use HRT or immunotherapy as individual treatment, although, the clinical research in the combination of both modalities is still premature. In this regard, a number of barriers might experience by exercising Sung et al. model, in which several blocks can be identified. Regulatory burden, Practice limitation, and lack of funding may consider as the root cause of delaying implementation of such combination. However, careful examination of other “blocks” would move such clinical research
more rapidly.

Tracks

  • Neuropeptide Y and its Y5 receptor: Novel therapeutic targets linking stress and breast cancer progressi
Location: Amsterdam, Netherlands
Speaker

WEISI YAN

Chair

Speaker

DWAYNE N. JACKSON

The University of Western Ontario, Canada

Co Chair

Biography

Wassil Nowicky is the Director of Nowicky Pharma and Presidentof the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) by the end of 1955 from graduation to Diplomingeniueur in 1960 whose title was nostrificated in Austria in 1975. He is the Author of over 300 scientific articles dedicated to cancer research. He is a real member of the New York Academy of Sciences, member of the European Union for Applied Immunology and of the American Association for scientific progress, Honorary Doctor of the Janka Kupala University in Hrodno, doctor honoris causa of the Open international university on Complex Medicine in Colombo, Honorary Member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmacists of America. the award of Austrian Society of sanitary, hygiene and publichealth services and others.

Abstract

One of the most significant problems of cancer therapy is the damaging activity
of anticancer drugs against normal body cells. All attempts to develop a therapeutic agent with a selective cytotoxic effect on tumor cells had no much
success because of the high degree of biological identity between healthy and
malignant cells. The celandine is being used in the medicine over more than 3500years. The first data concerning the therapeutic effect of the juice of celandine in the patient with malignant melanoma were published in Germany in 1536. From that time drugs based on biologically active substances of celandine are widely used to treat cancer and non-cancer disease. It is well known that tumor cell is more negatively charged as compared to normal cell. We have used this feature of the tumor cell to give NSC631570 a property to selectively interact with it, without endangering healthy cells and tissues. The drug is strongly positively charged. Due to this it has an ability to be selectively accumulated in tumor tissue and to inducetumor cell apoptosis only in tumor cells without harmful effect on normal cells.The potent selective antitumor effect of NSC631570 was repeatedly proven by he results of clinical trials. Until now this preparation has been tested on over 100cancer cell lines and on 12 normal cell lines and the results of the studies carried out in more than 120 universities and research centers (in particular at theNational Cancer Institute (the USA)) have shown that the NSC631570 killed only cancer cells without having damaged the normal cells that confirmed its selective and munomodulating effect.

Biography

Adnan Yousif Rojeab has done his Doctorate in Electrical Engineering; he is a University Lecturer and Researcher. He has also worked at the Queen Mary University of London, University of West London. He is currently working at the London College. His research interests include action of electromagnetic fields on human system.

Abstract

The cancer is a phenomenon of special reaction mechanism, which is functioning against the threat of severely acted tissues in the body. It is only created to eliminate severe damages and dangerous that occur in the cells of the body, when the immune system fails to cure the damages. The effect of the cancer could only be ended when a direct, right and simple treatment method
should be applied to cure the previous diseases that have caused the cancer, but not to attempt to treat the cancer itself. For the telomere matter, cancer cells have similar lengthening characteristics to those of germ and stem cells. While in somatic cells the telomere is shortening in every DNA replication. By applying a suitable amount and direction of a magnetic action on opposing the
cancer cells, it could be inhibited the lengthening of the telomere of the cancer cells, towards the somatic cells characteristics. This application could be accepted as a method of vanishing the cancer Introduction While the cancer subject is, generally, well known, then, the importance of this introduction is to explain the broad and significant factors of the cancer creation. The factors are those directly concerning with the main points to be discussed in this  ypothesis
research. Therefore, in this regard, it is relevant to avoid any biological or chemical details, and to concentrate on the points related to the main topic of this paper. Vital processes such as cell division and cell function are controlled by certain genes, where great damaging in some of these genes can lead to a cell to become cancerous [1]. Accordingly, cancer is a disease characterized, in literature, by the development of abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy normal body tissue. This is because the normal cells’ regulator mechanisms have been damaged. Then, when cells keep
continuously dividing, [while new cells are not required by the body], a tumour forms. The faulty genes may be inherited or caused by carcinogens (cancer-causing agents), such as radiation, sunlight, tobacco smoking and virus [2]. On the other hand cells are continually exposed to carcinogens, but they rarely become cancerous for some reasons such as: cells can usually repair damages; more than one gene must be damaged before cancer develops; and the body’s immune system often destroys any abnormal cells before they are able to multiply enough to form a cancerous tumour. If this process fails, then, cancer developing is a matter of severe damaging to specific genes. Also, cancer is a group of many different diseases [3], it depends on the causing factor and the area (tissue) been affected. The target of this hypothesis is to rise a vital guide strategy leading to considerable decrease in the number of sufferers from the can er. Conclusion The essential reason for the onset of the cancer on cells, is to eliminate the severe action against the vital process of the cell’s function. This means that the cancer has to be strategically understood in different manner than that of the traditional way. This understanding should be associated with the type of the treatment method, which is applied to heal the body from the cancer itself. The successful method of healing from cancer may occurred by full treatment method which is applied against the factors
that were causing the cancer. It is not by direct treatment applied to the cancer itself. Treatments by applying the traditional methods are believed to be danger. They are the methods of trying to treat the cancer, but, truly, they are helping to cause the onset of the cancer itself.

Biography

The first author is a founder of the Goodheart Institute & Foundation in Nature Medicine & Health, Rotterdam, The Netherlands, Freedom of Science and Education, European Free University Network. JJ Michiels is founder of the European Working Group on Myeloproliferative Disorder / Myeloproliferative Neopasms 1998-2018, co-founder of the Central European Vascular Forum (CEVF) and serves as consultant professor in the Bloodcoagulation, Hemostasis Research Laboratory (co-founder VWF-VWD research program) at
the department of Hematology University Hospital, Antwerp. JJ Michiels serves as consultant professor in Hematology and Bloodcoagulation, Comenius University, Bratislava, Slovakia; consultant to the Dutch Society of Internal Medicine and Ministery of Public Health; consultant of quality driven Industrial and Pharmaceutical Medicine; as an editor of 2 Medical Journals and as a guest editor on request and by self initiation. Writing assistance was utilised in the preparation of this lecture, it was carried out at the Goodheart Institute and Foundation in Nature Medicine and Health, Rotterdam,The Netherlands. The author has no other relevant affiliations or financial involvement with any organizationor entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Abstract

The broad spectrum of JAK2 V617F mutated trilinear myeloproliferative  neoplasms (MPN) include essential thrombocythemia(ET), prodromal polycythemia vera (PV), erythrocythemic PV, classical PV, masked PV and PV complicated by splenomegaly and myelofibrosis (MF). ET heterozygous for the JAK2V617F mutation is associated with low MPN disease burden and normal
life expectancy. JAK2V617F mutation load increases from less than 50% in prodromal and early stage PV to above 50% up to 100% in combined heterozygous/homozygous or homozygous JAK2V617F mutated PV, advanced PV and progressive myelofibrosis (MF). Pretreatment bone marrow morphology and cellularity distinguish JAK2V617F mutated trilinear MPN from calreticulin (CALR) and MPL mutated MPN. The morphology of clustered large pleomorphic megakaryocytes with hyperlobulated nuclei are similar in JAK2V67F ET and PV patients. CALR mutated thrombocythemia shows bone marrow characteristics of normocellular megakaryocytic (M) proliferation and subsequent dual megakaryocytic granulocytic (MG) myeloproliferation, first described in the 1990s as primary megakaryocytic granulocytic myeloproliferation (PMGM) without features of PV in blood and bone marrow. MPL515 mutated thrombocythemia is featured by monolinear proliferation of large to giant megakaryocytes with hyperlobulated staghorn like nuclei. Natural history and life expectancy relate to the degree of splenomegaly, myelofibrosis, constitutional symptoms and increased allele burden in JAK2V617F trilinear MPN and MPL515 thrombocythemia but CALR thrombocythemia runs a more favourable course during life-long follow-up. The acquisition of epigenetic mutations at increasing age predicts unfavorable outcome in JAK2, CALR and MPL mutated MPN. Low dose aspirin in ET and phlebotomy on top of aspirin in PV is mandatory to prevent platelet-mediated microvascular circulation disturbances. Pegylated interferon is the first line myeloreductive treatment option in prodromal and early stage JAK2V617F mutated PV and in CALR and MPL mutated thrombocythemia to postpone or obviate the targeted use of hydroxyurea and ruxolitinib as long as possible.

Biography

Jose Antonio Matute Briceño is currently the Submedical Director, Chief  Pathologist and Investigator from the Binational Sonora Cancer Research Center (CICS) in Seattle/ Sonora. One of its main functions is to carry out; immuno-advanced cancer reports, molecular pathology and immunological studies such as ELISA, ELISOPT, T cell expansion, and Immunogram. In the research area, developing scientific projects with Clinic relevance and performed experiments focused on patient's immune response against cancer.
He received specialist training in Pathology at the University of Monterrey; in 2014, began training in Immuno-Oncology at the OMA/CICS group, where he developed a diagnostic chart for the Imunoncopathology evaluation with prognostic and therapeutic implications He has participated in numerous international conferences of molecular pathology, oncology, USCAP, ASCO, ESMO, where he has made oral and posters presentations. He has been involved in some published scientific articles of the OMA group / CICS and 5
more in preparation.

Abstract

The impact of cancer immunotherapy on clinical cancer care is growing rapidly. However, different immunotherapies relay in different points of interactions between cancer and the immune system and there is not a reliable way to measure this impacts, outcomes, prognostics or predictive which patients are going to respond. We propose a framework for describing the different interactions between cancer and the immune system in individual bases. Our aiming is to focus on biomarker research and to enhance immune response. The proposed cancer immunogram assumes that T cell activity is the ultimate effector mechanism in human tumours (CD8+ GranzymeB+ and TH1 cells). Our immunogram takes into account 11 parameters which allow us to evaluate  comprehensively the immunological context of our patients. We measure this parameters: Cellular infiltration; Immunochemistry bad prognosis proteins); ELISA (humoral response) T Cell Expansion (T cell response), LISPOT (GranzymeB, IL-10, Gamma nterferon), DTH (Skin Biopsy), Tumoral Stroma, Blood Parameters (ALC, RLC, AMC, AEC), Soluble inhibitors (Fibrinogen, ESR, PCR), Tumor metabolism (DHL),T Cell subtype (CD8, Granzyme B, TH1, TH2, T. REG, DC, CD20, CD45RO, CD45RA). They are still aiting to further introduce factors like Microbiota, oral immunology (mouthwashes) and Flow cytometers, Liquid Biopsies, etc. We have performed this immunogram on prevention patients to see how we can modulate and predict possible tumours, we also used in recurrence prevention patients to monitor immune response to treatments and prevent possible recurrence; in active and refractory patients helps us to determine the best immunotherapy treatment and individualization of patients. This new approach gave us a complete panorama of the immunocontext re and will be very effective as a Pan biomarker for immunotherapy respondrate as a prognostic marker as well.

Biography

Kamlesh Guleria has completed his PhD from Guru Nanak Dev University, Amritsar, Punjab, India and Postdoctoral studies from Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne (UK). He also worked as Research Scientist at Sir Ganga Ram Hospital, New Delhi, India. Since 2009, he is working as Assistant Professor, at Department of Human Genetics Guru Nanak Dev University, Amritsar. He has published more than 20 papers in reputed journals and has  been serving as an Editorial Board Member of repute and he
has secured extramural research grants from various fundingagencies in India.

Abstract

Angiogenesis is an essential process in tumor growth, provides potential routes for tumor dissemination and metastasis. Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis and is involved in the evelopment and progression of solid tumors. Cancers use lymphangiogenesis and VEGF has been described as major mediator of breast cancer angiogenesis. The aim of the present study was to investigate the potential association of thirteen [ten promoter (-2578C/A,-2549I/D,-460T/C,-417T/C, -172C/A,-165C/T,-160C/T, -152G/A,-141A/Cand -116G/A),two 5′-UTR (+405C/G, -7C/T) and one 3′-UTR (+936C/T)] VEGF polymorphisms with breast cancer risk in patients from Punjab, North-west India. Inthis study,DNA samples of 250 pathologically confirmed breast cancer patients and 250 ages and gender matched unrelated healthy individuals were screened for thirteen selected VEGF polymorphisms using direct PCR, PCR-RFLP and Sanger sequencing methods. Of 250 breast cancer patients, 7 were males and 243 were females. About 73.6% of patients developed breast cancer after 40 years of age. A significant association of VEGF -2578AA, -2549II, -460CC, B+405GG, -152AA and -116AA genotypes with increased breast cancer risk were observed. VEGF -165CT and -141AC genotypes were associated with decreased risk for breast cancer. A strong linkage was observed between VEGF
-2578C/A and -2549I/D, -2578C/A and -460T/C,-2549I/D and -460T/C and -165C/T and -141A/C polymorphisms. Haplotype analyses indicated that EGF -2578A/-2549I/-460C/+405G/-7C/+936Cand-417T/-172C/-165C/-160C/ 152A/-141A/-116A combination was associated with increased risk while combination of -2578C/-2549D/-460T/+405G/-7C/+936C was associated with
decreased risk for breast cancer. Analysis using TFSEARCH software revealed
that VEGF -2578C/A, -417T/C, -172C/A and +405C/G polymorphisms altered
the binding site of specific transcription factors. In this case-control study, VEGF -2578C/A, -2549I/D, -460T/C, +405C/G, -165C/T, -152G/A, -141A/C and -116G/A polymorphisms were associated with susceptibility to breast cancer in patients from Punjab, North-west India. VEGF is an important target in anticancer therapy, and findings about polymorphisms influencing VEGF-targeted therapies will help physicians to tailor therapy in individual manner. Biography Kamlesh Guleria has completed his PhD from Guru Nanak Dev University, Amritsar, Punjab, India and Postdoctoral studies from Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne (UK). He also worked as ResearchScientist at Sir Ganga Ram Hospital, New Delhi, India. Since 2009, he is working as Assistant Professor, at Department of Human Genetics Guru Nanak Dev University, Amritsar. He has published more than 20 papers in reputed journals and has been serving as an Editorial Board Member of repute and he has secured extramural research grants from various funding agencies in India. guleria_k@yahoo.com mpact of functional polymorphisms of VEGF on breast cancer isk in North-west Indians amlesh Guleria1, Vasudha Sambyal1, Ruhi Kapahi1, Mridu Manjari2, eena Sudan2, Manjit Singh Uppal2 and Neeti Rajan Singh2 1Guru Nanak Dev University, India 2Sri Guru Ram Das Institute of Medical Sciences and Research, India Kamlesh Guleria et al., Arch Can Res 2018, Volume: 6 DOI: 10.21767/2254-6081-C2-008